```html

Vogt‑Koyanagi‑Harada Disease – A Complete Patient Guide

Overview

Vogt‑Koyanagi‑Harada disease (VKH) is a rare, multisystem autoimmune disorder that primarily attacks the melanocyte‑rich tissues of the eye, inner ear, meninges, skin, and hair. The disease is named after three early 20th‑century physicians—Alfred Vogt, Yoshizo Koyanagi, and Einosuke Harada—who independently described its characteristic findings.

• Who it affects: Most patients are adults aged 20‑50 years, with a slight female predominance (≈55 %).
• Ethnic predisposition: Higher incidence among individuals of Asian, Hispanic, Middle‑Eastern, or Native American descent. In Japan, the incidence is estimated at 2–3 per million per year, whereas in the United States it is <0.5 per million (CDC).
• Prevalence: Worldwide prevalence is low—roughly 1–2 cases per 100,000 population—but under‑recognition may cause modest under‑reporting.

VKH is classified as a T‑cell‑mediated autoimmune response against antigens associated with melanocytes. Because melanocytes are present in several organ systems, patients often present with a combination of ocular, auditory, neurologic, and cutaneous signs.

Symptoms

Symptoms evolve in three classic phases, but they can overlap. The list below includes every commonly reported manifestation.

Ocular Symptoms (most frequent)

• Blurred vision – often sudden or progressive over days.
• Photophobia – light sensitivity due to uveitis.
• Redness and ocular pain (usually mild).
• Decreased visual acuity – may progress to legal blindness if untreated.
• Floaters – caused by inflammatory cells in the vitreous.
• Serous retinal detachment – seen on imaging, can cause central scotoma.

Neurologic/Meningeal Symptoms (acute phase)

• Severe headache, often described as “meningeal” pain.
• Neck stiffness and photophobia (meningismus).
• Auditory disturbances – tinnitus, temporary hearing loss, or vertigo.
• Fever and general malaise.
• Encephalopathic signs – rare, include confusion or seizures.

Cutaneous and Hair Findings (late phase)

• Vitiligo‑like depigmentation of the skin, especially on the face and trunk.
• Poliosis – white patches of hair on the scalp, eyebrows, or eyelashes.
• Erythema or hyperpigmented macules that may appear weeks to months after ocular onset.

Other Possible Symptoms

• Dry eyes (keratoconjunctivitis sicca) due to chronic inflammation.
• Joint pain or mild arthralgias in some patients.

Causes and Risk Factors

The exact trigger of VKH remains unknown, but research points to a combination of genetic susceptibility and environmental exposure.

Immunologic Mechanism

• Auto‑reactive CD4⁺ T‑cells target melanocyte antigens (e.g., tyrosinase‑related proteins).
• Cytokine release (IFN‑γ, IL‑17, TNF‑α) drives granulomatous inflammation in the uvea, meninges, and skin.

Genetic Predisposition

• HLA‑DR4 and specifically the HLA‑DRB1*04:05 allele are strongly associated with VKH in Japanese, Chinese, and Hispanic populations (NIH).

Environmental Triggers

• Viral infections (e.g., influenza, Epstein‑Barr virus) have been reported preceding disease onset in case series, suggesting a possible “molecular mimicry” trigger.
• Occasional reports link VKH onset to trauma or ocular surgery, though causality is unproven.

Who Is at Higher Risk?

• Adults 20‑50 years old, especially of Asian, Hispanic, Middle‑Eastern, or Native American ancestry.
• Individuals with a family history of autoimmune disease (e.g., lupus, rheumatoid arthritis).
• People carrying HLA‑DR4 subtypes.

Diagnosis

Early recognition is vital because prompt treatment can preserve vision. Diagnosis is clinical, supported by imaging and laboratory work‑up.

Diagnostic Criteria (International Revised Criteria, 2001)

1. Mandatory ocular findings – bilateral granulomatous uveitis.
2. At least two of the following extra‑ocular signs:
   • Neurological (meningismus, tinnitus, cerebrospinal fluid pleocytosis)
   • Auditory (hearing loss, vertigo)
   • Cutaneous (vitiligo, poliosis, alopecia, erythema)
3. Exclusion of other causes (infectious uveitis, sarcoidosis, sympathetic ophthalmia, etc.).

Key Tests

• Comprehensive eye exam – slit‑lamp biomicroscopy, indirect ophthalmoscopy.
• Fundus fluorescein angiography (FFA) – shows multiple pinpoint hyperfluorescent leaks and pooled sub‑retinal fluid.
• Indocyanine green angiography (ICGA) – highlights choroidal stromal inflammation, an early marker.
• Optical coherence tomography (OCT) – detects serous retinal detachment and thickened choroid.
• Ultrasound B‑scan – measures choroidal thickness (>500 µm suggests active disease).
• Lumbar puncture (if neurological signs) – typically shows lymphocytic pleocytosis.
• Laboratory work‑up to rule out infections: CBC, ESR/CRP, syphilis serology, TB quantiferon, viral serologies.
• Optional: HLA typing – identifies DRB1*04:05, helpful in equivocal cases.

Treatment Options

The therapeutic goal is rapid control of inflammation to prevent irreversible ocular damage.

First‑Line: High‑Dose Systemic Corticosteroids

• Pulsed intravenous methylprednisolone 1 g/day for 3 days, followed by oral prednisone 1 mg/kg/day.
• Taper slowly over 6‑9 months while monitoring visual acuity and ocular inflammation.
• Side‑effects to monitor: hyperglycemia, hypertension, mood changes, osteoporosis.

Steroid‑Sparing Immunosuppressants

Added early to reduce long‑term steroid exposure.

• Azathioprine – 2–3 mg/kg/day.
• Mycophenolate mofetil – 1 g twice daily.
• Cyclophosphamide – IV 0.5–1 g/m² monthly (reserved for severe refractory disease).
• Cyclosporine – 3–5 mg/kg/day (monitor renal function and blood pressure).

Biologic Agents (for refractory or relapsing disease)

• Adalimumab (anti‑TNFα) – 40 mg subcutaneously every other week; FDA‑approved for non‑infectious uveitis.
• Infliximab – 5 mg/kg IV at weeks 0, 2, 6, then every 8 weeks.
• Rituximab – CD20‑targeted; limited case series show benefit.

Local Ocular Therapies

• Topical corticosteroid eye drops (e.g., prednisolone acetate 1 %) for anterior segment inflammation.
• Periocular or intravitreal corticosteroid injections (triamcinolone) in patients unable to tolerate systemic steroids.

Adjunctive Measures

• Calcium + vitamin D supplementation and bone‑protective agents (e.g., bisphosphonates) when long‑term steroids are needed.
• Blood pressure, glucose, and lipid monitoring.
• Patient education on medication adherence and recognition of relapse.

Living with Vogt‑Koyanagi‑Harada Disease

While VKH is chronic, many patients achieve disease control with medication and lifestyle adjustments.

Daily Management Tips

1. Medication schedule – use a pill organizer; set alarms for oral steroids and immunosuppressants.
2. Regular ophthalmology visits – at least every 1–2 months during active disease, then every 3–6 months once stable.
3. Protect your eyes – wear UV‑blocking sunglasses, avoid bright indoor lighting when photophobic.
4. Monitor systemic symptoms – keep a diary of headaches, hearing changes, or new skin patches and report promptly.
5. Maintain a healthy lifestyle – balanced diet, regular exercise, smoking cessation, and limiting alcohol (which can exacerbate steroid side‑effects).
6. Vaccinations – stay up‑to‑date (influenza, pneumococcal, COVID‑19) but avoid live vaccines while on high‑dose immunosuppression.

Psychosocial Support

• Join patient advocacy groups such as the American Uveitis Society for peer support.
• Consider counseling if vision loss or skin changes affect self‑esteem.

Prevention

Because VKH is autoimmune, there is no proven method to prevent its onset. However, risk reduction strategies are helpful for individuals with known susceptibility.

• Avoid known triggers – early treatment of viral infections, prompt management of ocular trauma, and cautious use of intra‑ocular surgery.
• Genetic counseling – may be considered for families with multiple affected members.
• Regular health checks – early detection of systemic autoimmune activity can spare vision.

Complications

If inflammation is not adequately controlled, permanent damage can occur.

• Permanent vision loss – due to chronic diffuse choroiditis, sub‑retinal fibrosis, or cataract formation.
• Glaucoma – secondary to prolonged steroid use or inflammatory angle closure.
• Choroidal neovascularization (CNV) – may require anti‑VEGF therapy.
• Hearing impairment – irreversible sensorineural loss in a minority of patients.
• Skin scarring – vitiligo patches can be cosmetically distressing.
• Systemic steroid toxicity – osteoporosis, diabetes, adrenal suppression.

When to Seek Emergency Care

For all other concerns, schedule an urgent appointment with your ophthalmologist or rheumatologist.

---

Sources: Mayo Clinic, Mayo Clinic; National Institutes of Health, NIH Uveitis Review; American Academy of Ophthalmology, AAO; World Health Organization, WHO; Cleveland Clinic, Cleveland Clinic.

```